Our brains are the key to who we are

At Re:Cognition Health we are committed to changing the future for those with memory loss and Alzheimer’s Disease. We provide education, clinical excellence and access to the most advanced treatments available, worldwide.

Contribute to the development of a cure for Alzheimer’s

It is an exciting time for research into Alzheimer’s disease and other causes of mild cognitive impairment (MCI) and dementia.

Results from clinical trials are always encouraging, bringing us ever closer to treatments to slow down or, ideally, halt the progression of the disease and to improve its symptoms.

World-class medical care for free

Volunteers receive outstanding medical care and are monitored regularly throughout the study by our team of brain and mental health experts. All medical costs are covered by the pharmaceutical company, so the very best care and medical facilities are provided at no cost to the individual.

Help us beat this devastating disease

Clinical trials are essential for advancing our understanding of medicine and improving the healthcare and quality of life for everyone affected by dementia and cognitive impairment.

Early access to new-generation medications

By participating in an international clinical study, you can gain the potential personal benefit of early access to a new treatment, whilst also having an important global impact on our ability to treat a given condition.

Global leader in enrolling volunteers onto clinical trials

Led by award-winning consultant neuroradiologist, Dr Emer MacSweeney, the Re:Cognition Health Clinical Trials team is proud of the pioneering work being undertaken by the consultants and cognitive experts at our clinics.

That’s why we continue to work hard to become one of the most successful clinics in the world for enrolling individuals onto final phase international clinical trials for Alzheimer’s Disease.

The welfare of our patients is at the heart of what we do

We have one goal: to help find a cure for Alzheimer’s Disease.

Frequently Asked Questions

Q) Will I be paid?

A) You will not be paid for your participation in the clinical trial, however, the sponsor will reimburse reasonable travel expenses for you and your study partner for each visit. To give you an example, for most of our current trials, the reimbursement is up to £60 for the patient and £60 for the study partner for each visit.

Q) How often are the visits?

A) The frequency of the visits will depend on the clinical trial that you participate in. The trials will have a period of frequent visits at the start during the screening period. The screening period is when all the initial investigations are carried out to establish whether an individual is eligible for the trial. During the treatment stage of the study, the visits will be less frequent. Some trials require a clinic visit once a month whereas others have visits every six 6 weeks. Once you are on a trial, we will be able to give you all your appointments in advance.

Q) Can I leave the trial before it finishes?

A) You can leave the trial at any point. Your medical or legal rights will not be affected. You do not need to give a reason as to why you want to leave, although we always value any feedback from you. If you choose to leave after you have started taking the trial drug, then we are obliged to offer you a final visit, called the termination visit.

Q) I have vascular dementia, can I take part?

A) No. All of our current clinical trials are for Alzheimer’s Disease. However, we are always investigating new studies so please register your contact details and we will get in touch when we have a trial that is suitable for you.

Q) Will I get my results?

A) As part of the trial, you will undergo various screening tests. These include a medical examination, blood pressure reading, urine tests, ECG, MRI head scan, a PET scan or lumbar puncture. You will be informed of all of you results and GP will also be made aware of any significant results.

Q) Will I have to take a trial drug?

A) Yes. If you are found to be eligible for one of the clinical trials, then you can consent to be assigned to a treatment group. Depending on the trial, the trial medication can be in the form of a tablet taken orally once a day or an intravenous infusion once a month.

Q) Will I know what I am taking?

A) No. You will not know whether you are taking the active study drug or a placebo. A placebo is a dummy pill and does not contain any active drug. You will be randomly assigned into one of the study groups and you and your study team will not know which group you are in. This is called a randomised, double-blind, placebo controlled trial.

Q) What if I am on placebo?

A) There is a chance that you are in the placebo group, the probability of that will depend on the trial. It may be anyway between 1:2 to 1:3. Whichever group you are in, you will still benefit from the ongoing medical care and psychometric testing that you will receive as part of the trial. At the end of the trial period, most trials offer the opportunity for you to enter the open label extension. This is when you continue in the trial but on the active drug despite whichever group (ie. Placebo or active drug) group you were in before. The open label extension is un-blinded, so you will know you are on the active drug.

Q) Are there any side effects?

A) Any potential side effects will be listed in the patient information sheets that are sent to you prior to your initial consultation. Most of the side effects are non-specific but some trials have specific side effects that your study doctor will discuss with you. We will work closely with you and your GP to ensure your safety at all times.

Q) What is a study partner and why do I need one?

A) A study partner is someone who can accompany the participant to some study visits and answer questions about their symptoms. They should be someone who sees the volunteer regularly e.g. a spouse, relative or close friend as they will need to let us know about any potential changes in the volunteer’s health or behaviour. The number of visits they need to attend depends on each study.

Q) Do I need to tell my GP?

A) Yes and no. It is good practice to let your GP know but it is not necessary to inform your GP before your screening visit. If you are found to be eligible for the study at the screening visit, we will inform your GP and obtain a medical summary letter from your GP with your consent. We can also write to other doctors involved in your care should you wish.

Q) Where can I take part?

A) Re:Cognition Health has clinics across the UK in London, Guildford, Plymouth and Birmingham. Our first clinic in the USA is scheduled to open in January 2018. For more information about our clinics click here